A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2008

Conditions
Advanced Malignancies
Interventions
DRUG

MLN8054

"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"

Trial Locations (1)

08035

Ciutat Sanitaria Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00652158 - A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter